CVM - Why Is Cancer Focused CEL-SCI Stock Trading Higher Today? | Benzinga
CEL-SCI Corporation (AMEX: CVM) announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine (Leukocyte Interleukin, Injection) to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck (SCCHN) in the U.K.
The NICE Full story available on Benzinga.com